Project description DEENESFRITPL Digital respiratory treatment and inhalation coach COPD and Asthma are serious life-threatening lung diseases and are predisposed to exacerbations. They are the most common chronic respiratory diseases (CRDs). While not curable, they can be treated by delivering medication into the lungs using inhalers. Unfortunately, 90 % of patients use their inhalers incorrectly resulting in insufficient medication and a treatment below best possible outcome. The EU-funded KATA app is a personalised, AI-driven, digital assistant to help respiratory patients inhale their medication more effectively. The Kata smartphone app shows how to inhale correctly by providing real-time guidance and feedback. In combination with medical value records, an exercise programme and educational content, the app aims to be a complete personal respiratory disease coach. Show the project objective Hide the project objective Objective IIncreasing industrialization in emerging countries, high levels of pollution and smoking is leading to a rise in chronic respiratory diseases (CRDs) worldwide. Even though CRDs are not curable, there are efficient treatments against them, mainly delivering medication into the lungs using inhalers. Unfortunately, 90% of the patients are not using correctly their inhalers, leading to chronic under-use of the prescribed medication and poor management of the disease. VisionHealth, founded in 2017, provides CRD patients with a unique therapy companion to efficiently manage CRDs – the Kata app. With Kata, dynamic training and personalized feedback for optimal use of any commercial inhaler is, for the first time, possible using a combination of advance technology: (1) Machine Vision (MV) using a SIFT algorithm to discern among inhalers and handling, (2) Voice Recognition (VR) recognizing the drug intake and predicting it with RNN architecture, (3) Machine Learning (ML) linking MV and VR inputs and creating models to predict users’patterns, and (4) Augmented Reality (AR) guiding the user in real time based on the ML input. Kata will empower its users to master the usage of their inhaler by Kata’s personalized digital assistance. Kata will ensure high medication compliance in each inhalation to improve patient’s quality of life and functional capacities. Customers of Kata, healthcare insurance companies (HiCs) and pharmaceutical companies, will be able to reduce costs associated with poor patient health outcome and low adherence to medication. Moreover, these companies will be able to redefine their policies moving towards a patient-centered healthcare using the data collected from Kata’s users. VisionHealth aims at stablishing their business strategies and technical roadmap to launch an advance app into the market that will improve CRD patient’s health and, in addition, will provide highly valuable data to optimize HiCs’ and pharmaceutical companies’ activities. Fields of science medical and health sciencesclinical medicinepneumologyasthmamedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsnatural sciencescomputer and information sciencesartificial intelligencecomputer visionmedical and health scienceshealth sciencesinfectious diseasesRNA virusescoronavirusesnatural sciencescomputer and information sciencesartificial intelligencemachine learning Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator VISIONHEALTH GMBH Net EU contribution € 50 000,00 Address Landsberger strasse 72 80339 Munchen Germany See on map Region Bayern Oberbayern München, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
